Your browser doesn't support javascript.
loading
The recommendation of re-classification of variants of uncertain significance (VUS) in adult genetic disorders patients.
Zhang, Li; Shen, Minna; Shu, Xianhong; Zhou, Jingmin; Ding, Jing; Lin, Huandong; Pan, Baishen; Zhang, Chunyan; Wang, Beili; Guo, Wei.
Afiliación
  • Zhang L; Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Shen M; Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Shu X; Department of Echocardiography, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China.
  • Zhou J; Department of Cardiology Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Ding J; Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Lin H; Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Pan B; Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Zhang C; Department of Laboratory Medicine, Shanghai Geriatric Medical Center, Shanghai, China.
  • Wang B; Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. wang.beili1@zs-hospital.sh.cn.
  • Guo W; Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. guo.wei@zs-hospital.sh.cn.
J Hum Genet ; 69(9): 425-431, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38839994
ABSTRACT
Since variants of uncertain significance (VUS) reported in genetic testing cannot be acted upon clinically, this classification may delay or prohibit precise diagnosis and genetic counseling in adult genetic disorders patients. Large-scale analyses about qualitatively distinct lines of evidence used for VUS can make them re-classification more accurately. We analyzed 458 Chinese adult patients WES data, within 15 pathogenic evidence PS1, PS2, PM1, PM6 and PP4 were not used for VUS pathogenic classification, meanwhile the PP3, BP4, PP2 were used much more frequently. The PM2_Supporting was used most widely for all reported variants. There were also 31 null variants (nonsense, frameshift, canonical ±1 or 2 splice sites) which were probably the disease-causing variants of the patients were classified as VUS. By analyzed the evidence used for all VUS we recommend that appropriate genetic counseling, reliable releasing of in-house data, allele frequency comparison between case and control, expanded verification in patient family, co-segregation analysis and functional assays were urgent need to gather more evidence to reclassify VUS. We also found adult patients with nervous system disease were reported the most phenotype-associated VUS and the lower the phenotypic specificity, the more reported VUS. This result emphasized the importance of pretest genetic counseling which would make less reporting of VUS. Our result revealed the characteristics of the pathogenic classification evidence used for VUS in adult genetic disorders patients for the first time, recommend a rules-based process to evaluate the pathogenicity of VUS which could provide a strong basis for accurately evaluating the pathogenicity and clinical grade information of VUS. Meanwhile, we further expanded the genetic spectrum and improve the diagnostic rate of adult genetic disorders.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Pruebas Genéticas / Asesoramiento Genético / Enfermedades Genéticas Congénitas Límite: Adult / Female / Humans / Male Idioma: En Revista: J Hum Genet Asunto de la revista: GENETICA MEDICA Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Pruebas Genéticas / Asesoramiento Genético / Enfermedades Genéticas Congénitas Límite: Adult / Female / Humans / Male Idioma: En Revista: J Hum Genet Asunto de la revista: GENETICA MEDICA Año: 2024 Tipo del documento: Article País de afiliación: China